Anorexia and bulimia incidence rose 71% from 1990 to 2023 to 18.1 million cases with GLP-1 misuse documented in clinical reports

Ruhai Bai and colleagues at Nanjing Medical University aggregated population surveys across 204 countries and applied statistical models to estimate annual incidence and disability-adjusted life years. The analysis documented 3.83 million DALYs lost in 2023 from these two disorders alone. Projections indicate 21.8 million affected individuals by 2050 if trends persist. Social media exposure metrics from the same period show parallel growth in filtered imagery and diet-related content, though the study did not quantify algorithmic amplification effects.

Clinical observations from University of Louisville and University of North Carolina programs report increased severity and frequency of presentations coinciding with semaglutide and tirzepatide availability. Levinson documented patients restricting intake further via GLP-1s after initial prescription, triggering or worsening anorexia and bulimia cycles. Bulik noted that external restriction events reliably precipitate disorder onset in genetically susceptible individuals, a pattern now observed with these pharmacotherapies.

The JAMA data and clinic reports together indicate that digital platforms and GLP-1 access function as sequential environmental triggers rather than isolated factors. Regulatory tracking of off-label GLP-1 prescriptions and social media diet content exposure remains absent, leaving incidence forecasts conservative. Operational response requires integration of prescription monitoring with eating disorder screening protocols at scale.

Next steps include prospective cohort studies linking GLP-1 initiation dates to disorder onset timestamps and platform-level content audits for diet-restriction promotion. Threshold for measurable impact: 10% reduction in new diagnoses within five years if both pharmaceutical controls and algorithmic exposure limits are implemented concurrently.